ethyl 2-(piperazin-1-yl)acetate hydrochloride | 259808-38-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-(piperazin-1-yl)acetate hydrochloride
• 英文别名: ethyl 2-piperazin-1-ylacetate;hydrochloride
• CAS: 259808-38-3
• 化学式: C₈H₁₆N₂O₂*ClH
• 分子量: 208.688
• InChiKey: PQNHDYLVDFNODO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.12
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  41.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 储存条件：
  存储条件：室温、密封、干燥

反应信息

• 作为反应物：
  描述：

  ethyl 2-(piperazin-1-yl)acetate hydrochloride 在 盐酸羟胺 、 N,N-二异丙基乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 18.0h， 生成 N-hydroxy-2-(4-phenylacetyl-piperazin-1-yl)-acetamide
  参考文献：
  名称：

  Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors

  摘要：

  We report here the strategy used in our research group to find a new class of histone deacetylase (HDAC) inhibitors.A series of N-substituted 4-alkylpiperazine and 4-alkylpiperidine hydroxamic acids, corresponding to the basic structure of HDAC inhibitors (zinc binding moiety-linker-capping group) has been designed, prepared, and tested for HDAC inhibition.Linker length and aromatic capping group connection were systematically varied to find the optimal geometric parameters. A new series of submicromolar inhibitors was thus identified, which showed antiproliferative activity on HCT-116 colon carcinoma cells. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.085
• 作为产物：
  描述：

  1-Boc-4-乙氧基羰基甲基哌嗪 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.0h， 以77%的产率得到ethyl 2-(piperazin-1-yl)acetate hydrochloride
  参考文献：
  名称：

  Compounds and Their Use in Treating Cancer

  摘要：

  本说明书一般涉及公式(I)的化合物： 以及药学上可接受的盐和前药，其中R1、R4、R5、R6、R7、Linker、X、Y、A、G、D和E具有此处定义的任何含义。本说明书还涉及将此类化合物以及药学上可接受的盐和前药用于治疗人体或动物体的方法，例如用于预防或治疗癌症。本说明书还涉及制备此类化合物涉及的工艺和中间化合物，以及含有它们的药物组合物。

  公开号：

  US20190194190A1

文献信息

• 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：US20150336962A1

  公开（公告）日：2015-11-26

  Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

  这里描述了化合物的公式（00A）及其作为Janus激酶抑制剂的使用方法。
• Synthesis and biological activities of 3-aminomethyl-1,2-dihydronaphthalene derivatives.
  作者：KATSUMI ITOH、AKIO MIYAKE、MASAO TANABE、MINORU HIRATA、YOSHIKAZU OKA

  DOI：10.1248/cpb.31.2006

  日期：——

  A series of 3-aminomethyl-1, 2-dihydronaphthalene derivatives (6-22) was prepared from the corresponding 3, 4-dihydro-1 (2H)-naphthalenone derivatives (24a-q) in three steps, namely the Mannich reaction, reduction of the carbonyl group with sodium borohydride, and dehydration with ethanolic hydrogen chloride. Compounds 6-22 and several related analogs (23, 27-30) were tested for vasodilating and antihypertensive activities. Potent cerebral vasodilating and antihypertensive activities were exhibited by 1-benzhydryl-4-(7-disubstituted amino-1, 2-dihydro-3-naphthyl) methylpiperazines (16, 18 and 19).

  一系列3-氨基甲基-1,2-二氢萘衍生物（6-22）通过三步反应从相应的3,4-二氢-1(2H)-萘酚酮衍生物（24a-q）制备得到，这三步反应分别是曼尼希反应、用硼氢化钠还原羰基和用乙醇氢氯酸脱水。化合物6-22及其相关类似物（23, 27-30）被测试了血管舒张和抗高血压活性。1-二苯甲基-4-(7-二取代氨基-1,2-二氢-3-萘基)甲基哌嗪（16,18和19）展现了强大的脑部血管舒张和抗高血压活性。
• [EN] COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT<br/>[FR] COMPOSITIONS ET MÉTHODES POUR RÉDUIRE UN DYSFONCTIONNEMENT TACTILE, L'ANXIÉTÉ ET UNE DÉFICIENCE SOCIALE
  申请人：HARVARD COLLEGE

  公开号：WO2019232046A1

  公开（公告）日：2019-12-05

  The present invention features novel peripherally-restricted non-benzodiazipene analogs with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome, or for treating touch over-reactivity, pain, or mechanical allodynia.

  本发明涉及一种新型的周围限制非苯二氮平类似物，其具有降低血脑屏障渗透性的特点，以及使用该类似物的方法，用于减少被诊断为自闭症谱系障碍、雷特综合征、费兰基综合征或脆性X综合征的患者的触觉功能障碍、社交障碍和焦虑症状，或用于治疗触摸过度反应、疼痛或机械性痛觉过敏。
• Novel sulfonyl derivatives
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：US20040082611A1

  公开（公告）日：2004-04-29

  Described in the present invention are a sulfonyl derivative represented by the following formula (I): Q 1 -Q 2 -T 1 -Q 3 -SO 2 -Q A (I) [wherein Q 1 represents a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group, 5- or 6-membered heterocyclic group, dicyclic fused ring or tricyclic fused ring group which may have a substituent; Q 2 represents a single bond, an oxygen atom, a sulfur atom, a linear or branched C 1-6 alkylene group or the like; Q A represents an arylalkenyl group which may have a substituent or a heteroarylalkenyl group which may have a substituent; and T 1 represents a carbonyl group or the like] and a medicament comprising the same. The compound has strong FXa inhibitory action, provides prompt, sufficient and long-lasting anti-thrombus effects when orally administered, and has low side effects and is therefore useful as an excellent anticoagulant.

  本发明描述了一种由以下式(I)表示的磺酰基衍生物： Q1-Q2-T1-Q3-SO2-QA(I) [其中，Q1表示饱和或不饱和的5-或6-环烃基、5-或6-杂环基、二环融合环或三环融合环基，可能具有取代基；Q2表示单键、氧原子、硫原子、线性或支链的C1-6烷基等；QA表示可能具有取代基的芳基烯基或杂芳基烯基；T1表示羰基基团或类似物]，以及包含该化合物的药物。该化合物具有强烈的FXa抑制作用，口服后提供快速、充分和持久的抗血栓效果，并且具有低副作用，因此可用作优秀的抗凝剂。
• Sulfonyl derivatives
  申请人：Daiichi Pharmaceutical Co., Ltd.

  公开号：US06747023B1

  公开（公告）日：2004-06-08

  Described in the present invention are a sulfonyl derivative represented by the following formula (I): Q1—Q2—T1—Q3—SO2—QA  (I) [wherein Q1 represents a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group, 5- or 6-membered heterocyclic group, dicyclic fused ring or tricyclic fused ring group which may have a substituent; Q2 represents a single bond, an oxygen atom, a sulfur atom, a linear or branched C1-6 alkylene group or the like; QA represents an arylalkenyl group which may have a substituent or a heteroarylalkenyl group which may have a substituent; and T1 represents a carbonyl group or the like] and a medicament comprising the same. The compound has strong FXa inhibitory action, provides prompt, sufficient and long-lasting anti-thrombus effects when orally administered, and has low side effects and is therefore useful as an excellent anticoagulant.

  本发明涉及一种磺酰基衍生物，其由以下式（I）表示：Q1-Q2-T1-Q3-SO2-QA（I）[其中，Q1代表饱和或不饱和的5-或6-成员环烃基，5-或6-成员杂环基，二环融合环或三环融合环基，可以有取代基；Q2代表单键，氧原子，硫原子，线性或支链C1-6烷基或类似物；QA代表芳基烯基，可以有取代基，或杂环芳基烯基，可以有取代基；T1代表羰基或类似物]，以及包含该化合物的药物。该化合物具有强烈的FXa抑制作用，在口服时提供迅速，充分和持久的抗血栓效果，并且副作用低，因此是一种优秀的抗凝剂。